News | August 22, 2016

Mount Sinai Brings EpiAccess System for Cardiac Arrhythmias to New York

System offers needle with fiber-optic tip for improved real-time location data during epicardial procedures

EpiAccess System, EpiEP, Mount Sinai New York, epicardial access

August 22, 2016 — The Mount Sinai Hospital is the first site in the New York metropolitan area to pioneer a new approach for the treatment of cardiac arrhythmias using the EpiAccess system. Developed by medical device company EpiEP Inc., the EpiAccess system is a specialized instrument that facilitates an epicardial approach for non-surgical procedures on the surface of the heart.

“We are pleased to be among the first facilities in the nation to offer the EpiAccess system,” said Vivek Reddy, M.D., director of cardiac arrhythmia services at The Mount Sinai Hospital and the Mount Sinai Health System. “By providing routine and safe access to the pericardial space, the device offers a new approach to treat arrhythmias from the outside of the heart, enabling enhanced safety in advanced procedures and opening a new frontier for treating our patients.”

Non-surgical epicardial access has traditionally been limited by the two-dimensional image of a needle guided by intermittent fluoroscopy, which makes it difficult to know the precise location of the needle tip when accessing this small space surrounding the heart. The EpiAccess needle’s fiber-optic tip provides real-time pressure frequency data and immediate confirmation to alert physicians about needle tip location during the procedure. It was designed to reduce the risk of complications such as pericardial effusions, procedure time and exposure to radiation used during these types of procedures.

These first procedures with the EpiAccess system were performed by Srinivas Dukkipati, M.D., co-director of cardiac arrhythmia services at The Mount Sinai Hospital.

Reddy serves as an uncompensated consultant for EpiEp. He also owns equity in EpiEp (a privately traded company) in the form of stock options.

For more information: www.epiep.com


Related Content

News

April 26, 2026 — New results from the multicenter catheter ablation versus anti-arrhythmic drugs for Ventricular ...

Home April 29, 2026
Home
News

April 24, 2026 — Johnson & Johnson recently announced the initiation of the PERSIGMA randomized controlled trial (RCT) ...

Home April 27, 2026
Home
News

April 26, 2026 – New results from the pivotal multicenter trial FULCRUM-VT show that ultra-low temperature ablation ...

Home April 27, 2026
Home
News

April 13, 2026 — Johnson & Johnson has announced favorable 12-month interim effectiveness and safety results from ...

Home April 13, 2026
Home
News

In a milestone for Broward Health in Ft. Lauderdale, Fla., Jose L. Baez-Escudero, M.D., chief of cardiology and ...

Home March 24, 2026
Home
News

Feb. 6, 2026 — Abbott has announced new clinical data from two late-breaking presentations at AF Symposium in Boston ...

Home February 06, 2026
Home
News

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat ...

Home January 22, 2026
Home
News

Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the ...

Home January 21, 2026
Home
Feature | Kyle Hardner

Robotic Magnetic Navigation (RMN) emerged two decades ago as an alternative approach to performing complex ablation ...

Home January 09, 2026
Home
News

Jan. 6, 2026 — Stereotaxis, a supplier of surgical robotics for minimally invasive endovascular intervention, has ...

Home January 06, 2026
Home
Subscribe Now